adobe stock photos - deemerwhaBritish mitochondrial dysfunction specialist NRG Therapeutics Ltd. (“NRG”) has closed an oversubscribed £50m Series B financing. Funds will be used to to achieve clinical proof of concept in amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) and to generate Phase Ib data in Parkinson’s disease.
Tag Archive for: Parkinson’s
Image by Pete Linforth from Pixabay.Angelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.